Fulgent Genetics: High Insider Ownership Supports Asymmetric Upside

Group 1 - Fulgent Genetics is a biotech company specializing in diagnostics, particularly cancer screening tests [1] - The company experienced significant profitability over the last three years due to its successful COVID-19 testing segment [1] - The stock performance of Fulgent Genetics has been notable over the past five years [1]